CerSci Therapeutics

About:

CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute and chronic pain.

Top Investors: National Institutes of Health

Description:

CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received approval of their Investigational New Drug (IND) application for CT-044 from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed (commence phase I dosing June 2019). CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.

Total Funding Amount:

$13.9M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Dallas, Texas, United States

Founded Date:

2015-02-01

Founders:

Greg Dussor, Lucas Rodriguez, Scott Dax, Ted Price

Number of Employees:

1-10

Last Funding Date:

2019-03-16

IPO Status:

Private

Industries: